<DOC>
	<DOCNO>NCT00127998</DOCNO>
	<brief_summary>Resistance Plasmodium falciparum ( malaria ) current antimalarial drug continue development resistance new antimalarial formulation one major obstacle effective malaria control case management . Efficient , comprehensive validate method monitor drug resistance advance development resistance antimalarial drug use urgently need . Molecular marker genetic polymorphism give rise resistant P. falciparum parasites method population genetics evaluate data valuable tool monitor drug resistance field . This study aim : 1 . Prospectively measure vivo response P. falciparum malaria Mali several different antimalarial drug drug combination : chloroquine ( CQ ) , sulfadoxine-pyrimethamine ( SP ) , amodiaquine ( AQ ) , sulfadoxine-pyrimethamine combination amodiaquine ( SP/AQ ) , amodiaquine combination artesunate ( AQ/AS ) , sulfadoxine-pyrimethamine combination artesunate ( SP/AS ) , artemether-lumefantrine ( Co-artem ) . In one site preliminary data show high rate P. falciparum resistance mefloquine ( MQ ) , drug also test . 2 . Measure frequencies molecular marker antimalarial drug resistance , examine result relate efficacy drug treat clinical malaria 3 . Measure drug level 3 day correlate efficacy result . 4 . Examine early clinical , parasitologic , clinical predictor late treatment failure . 5 . Use knowledge gain Aims 1-3 develop molecular tool countrywide resistance surveillance system antimalarial drug .</brief_summary>
	<brief_title>Antimalarial Drug Resistance Mali</brief_title>
	<detailed_description>Resistance Plasmodium falciparum current antimalarial drug continue development resistance new antimalarial formulation one major obstacle effective malaria control case management . Parasite population highly resistant chloroquine almost worldwide basis ( Central America Haiti exception ) resistance next line treatment , SP , widespread Asia large part East Africa South America . SP also recommend use intermittent preventative treatment ( IPT ) pregnancy , add concern development spread SP resistance . More expensive combination drug therapy use artesunate antimalarial combination increasingly recommended effort extend useful life drug slow spread antimalarial drug resistance . In likelihood , resistance eventually emerge new single drug combination formulation deploy field . Given , efficient , comprehensive validate method monitor drug resistance advance development resistance antimalarial drug use urgently need . Such method would help malaria control prevention program guide national treatment recommendation policy . Integrating laboratory expertise , analytic method base population genetics , traditional method surveillance anti-malarial drug resistance ( e.g . vivo drug efficacy study ) network national international partner result multidisciplinary , geographically diverse team approach assess monitoring drug resistant malaria , well develop validate molecular method . This type effort greatly assist maximize useful life span antimalarial drug provide evidence-based guidance drug policy decision . Specific Aims : 1 . Prospectively measure vivo response P. falciparum malaria Mali CQ , SP , AQ , SP/AQ combination , AQ/artesunate ( AS ) combination , SP/AS , artemether-lumefantrine ( Co-artem ) . In one site preliminary data show high rate P. falciparum resistance MQ , MQ also test . 2 . Measure frequencies dihydrofolate reductase ( dhfr ) , dihydropteroate synthetase ( dhps ) , P. falciparum chloroquine resistance transporter ( pfcrt ) P. falciparum multi-drug resistant ( pfmdr 1 ) genotype establish relationship vivo resistance SP ( dhfr dhps ) , CQ , AQ , SP/AQ , AQ/AS , SP/AS , MQ . 3 . Measure drug level 3 day correlate vivo efficacy result . 4 . Examine early clinical , parasitologic , clinical predictor late treatment failure . 5 . Use knowledge gain Aims 1-3 develop molecular tool countrywide resistance surveillance system SP , AQ , MQ . Study Design : The study entail two consecutive year prospective 28 day vivo drug efficacy study carry rainy season three different malaria transmission site : Koro ( rural town 71 % resistance MQ low dose 15 mg/kg ) , Pongono ( rural town little exposure antimalarial ) Faladje ( rural village &gt; 30 % chloroquine resistance ) . Children age 6-59 month clinical symptom consistent malaria enrol study screen fever ( axillary temperature &gt; =37.5 C ) malaria asexual parasite identify microscopic examination thick blood film . Blood spot onto filter paper collect prior treatment follow . These filter paper sample use molecular detection drug resistance-conferring gene polymorphism well HPLC detection quantification respective drug relevant metabolite . In vivo data interpretation do use WHO 28-day protocol ( WHO , 2003 ) molecular marker use determination genotype resistance index ( GRI ) . Venous blood collect enrollment time vivo failure measure vitro drug efficacy cryopreserve parasites search novel molecular marker new antimalarial drug .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Amodiaquine , artesunate drug combination</mesh_term>
	<criteria>Aged 659 month Absence severe malnutrition ( defined child whose weightforheight 3 standard deviation less 70 % median World Health Organization ( WHO ) reference value , symmetrical edema involve least foot ) A slideconfirmed infection P. falciparum ( i.e . mixed infection ) Initial parasite density 2,000 200,000 asexual parasite per microliter . Absence general danger sign among child &lt; 5 year ( inability drink breastfeed ; vomit everything ; recent history convulsion ; lethargy unconsciousness ; inability sit stand ) sign severe complicate falciparum malaria accord WHO definition Measured axillary temperature ≥ 37.5 °C Ability attend stipulate followup visit Informed consent provide parent/guardian Absence history hypersensitivity reaction drug evaluate Aged &lt; 6 &gt; 59 month Severe malnutrition ( defined child whose weightforheight 3 standard deviation less 70 % median WHO reference value , symmetrical edema involve least foot ) No slide confirm infection P. falciparum mixed infection include non P. falciparum specie Initial parasite density &lt; 2,000 &gt; 200,000 asexual parasite per microliter . Presence general danger sign among child &lt; 5 year ( inability drink breastfeed ; vomit everything ; recent history convulsion ; lethargy unconsciousness ; inability sit stand ) sign severe complicate falciparum malaria accord WHO definition Measured axillary temperature &lt; 37.5 °C Inability attend stipulate followup visit Unwilling provide inform consent provide parent/guardian History hypersensitivity reaction drug evaluate</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>drug resistance</keyword>
	<keyword>antimalarial</keyword>
	<keyword>genotype</keyword>
	<keyword>treatment outcome</keyword>
</DOC>